Centene Q3 2026: $311M of severance drove a $0.14 loss; adjusted EPS rose to $0.58 and guidance went up

Centene's third quarter shows two different pictures. On a GAAP basis it lost $71 million, or $0.14 per share, because it booked $311 million of severance and outside-consultant costs for a company-wide cost-cutting program ("enterprise optimization"). Strip those out and adjusted earnings were $0.58 per share, up from $0.50. Total revenue rose 1.9% to $50.6 billion, even though Centene covers 2.3 million fewer people than a year ago: its ACA Marketplace membership fell 42%. Management raised its full-year adjusted EPS floor by $0.40 to more than $5.20.

The quarter in figures

n.m. = not meaningful. Q3 2025 included a $6.7 billion goodwill impairment (a write-down of the value of past acquisitions), so year-over-year percentages on the loss lines say nothing about the business.

Operating margin, the share of revenue left after running the business and before interest and tax, was negative this quarter because of the severance charge. Thin margins are normal for government-program insurers. Centene's full-year HBR guidance of 90.4–91.1% means roughly 91 cents of every premium dollar goes to medical care.

Takeaway: The GAAP loss is a one-quarter charge for cutting costs, and the business underneath it improved. Adjusted pre-tax earnings rose about 38% while the company shrank by 2.3 million members. The improvement comes from repricing and from the drug-plan business. Medicaid, the largest segment, did not improve: its HBR was 93.6%, worse than 93.4% a year ago.

Segments: Medicare carried the quarter

Gross margin is premium and service revenue minus medical costs and cost of services, before overhead. Segment HBRs are from Centene's Q3 earnings release (8-K Exhibit 99.1, October 27, 2026).

Medicare (+$161M gross margin). Revenue rose 20%, mostly from the stand-alone prescription drug plan (PDP) business. PDP membership grew 12% to 8.95 million, and premiums per member rose. Medicare Advantage and related plans shrank 5.8% to 954,400 members. The 10-Q credits "rate increases partially offset by pharmacy and medical costs." The year-on-year gain is understated, not overstated: in Q3 2025, Centene released $107 million of its premium deficiency reserve (money set aside in advance for Medicare Advantage contracts expected to lose money), which helped that quarter. In 2026 there is no such reserve to release. The earnings release says the quarter's HBR beat Centene's own expectations "driven by the Medicare segment."

Commercial (−$158M gross margin). Marketplace membership fell 42% to 3.40 million. The filing ties this to the expiry of the enhanced ACA premium tax credits, a federal rule tightening Marketplace eligibility (the "Final Rule"), and Centene's own price increases. The members who stayed are sicker on average, and Centene priced for that. HBR improved to 89.0% because of "improved pricing and risk transfer reflecting the acuity of the Marketplace membership." Risk transfer is the ACA mechanism that moves money from insurers with healthier members to insurers with sicker ones. Off-exchange individual and group membership, which includes employer-funded CHOICE arrangements (formerly ICHRA), rose 11% to 497,400.

Medicaid (flat gross margin). Revenue rose 6%, but the filing says that was "primarily driven by pass-through payments and rate increases." Membership fell 6.4% to 11.90 million as states continue to re-check eligibility. Gross margin slipped $4 million because Q3 2025 included "the non-recurring benefit from a retroactive adjustment." Even allowing for that, an HBR of 93.6% leaves little room for profit in Centene's biggest business.

What the headline numbers hide

• The GAAP loss comes from one charge. Severance for enterprise optimization and contract exits ($276M) plus outside vendor costs ($35M) total $311M pre-tax, or $0.63 per share before tax. The adjustments also include an $18M real-estate gain, a $15M loss on a prior divestiture and $161M of acquired-intangible amortization, which recurs every quarter. Adjusted pre-tax earnings, which add back amortization and these other items, were $346M versus $250M a year earlier, up about 38%. Full-year guidance assumes about $0.98 per share of "other adjustments" against $0.72 so far, so more restructuring cost is coming in Q4.
• The tax rate helped adjusted EPS in both years. The effective tax rate on adjusted earnings was 14.5% this quarter and 2.5% in Q3 2025, against full-year guidance of 25.5–26.5%. Both quarters reflect a catch-up to the estimated annual rate. At a 26% rate, adjusted EPS would have been about $0.51 versus about $0.38 a year earlier (our calculation). The like-for-like gain is larger than the reported +16%, but the $0.58 itself is inflated by about $0.07.
• Investment income fell. Investment and other income dropped $117M to $333M, "primarily driven by a realized loss on the sale of investments from rebalancing a portion of our portfolio" and asset disposals tied to the cost program. Centene did not adjust these out, so the drop weighs on adjusted EPS too. Interest expense fell $21M to $149M because Centene repurchased debt.
• Cash flow swung negative, and Centene had said it would. Operations used $3.7B of cash in Q3, which the company attributes to "the timing of pass through, premium and other payments, as expected." For nine months, operating cash flow was $4.3B against net earnings of $2.6B, so cash still covers earnings over the year to date. Premium and trade receivables grew $2.3B in nine months. Days in claims payable, the number of days of medical costs held in reserve, was 48, up one day from Q2. That is a mildly conservative sign.
• There were no buybacks. Centene bought back no stock under its program in Q3. The cash flow statement shows $57M of stock repurchases for the nine months; it gives no figure for the quarter alone. Diluted weighted shares rose 0.6% to 494.1M, so share count did nothing for EPS. Cash went to debt instead: $558M of senior notes were repurchased in Q3, the remaining $569M of 2027 notes were redeemed in October, and debt-to-capital fell to 41.1% from 46.5% at year-end. Centene pays no dividend.

On balance the quarter is understated: the $(0.14) GAAP loss comes from $311M of severance and vendor costs. Adjusted pre-tax earnings rose about 38%, though a 14.5% tax rate adds about $0.07 to the $0.58 adjusted figure.

Did last time's read hold up?

Our Q2 report said the guidance "points to a much weaker second half" and left room for an adjusted loss of roughly $1 per share in July–December. It also flagged Medicaid rate adequacy and noted that part of the Q2 gain was non-recurring. The quarter was weaker, as expected: HBR rose to 92.7% from 89.6% in Q2. But it came in better than the guidance implied, with an adjusted profit of $0.58 rather than a loss, and Centene raised its floor by $0.40. The Medicaid concern still stands. Segment HBR was 93.6%, slightly better than 93.9% in Q2 but worse than a year ago.

Two items we listed as 2027 factors have changed:

• California immigration-status transition. The number of Medi-Cal members leaving managed care is now estimated at about 175,000 at-risk members, down from the roughly 250,000 we cited.
• Medicare Advantage star ratings. These turned negative for 2028. Only about 42% of members are in plans rated 3.5 stars or higher for 2028 payments, down from about 60% for 2027, and 4-star membership fell to 10% from 20%. Higher-rated plans earn bonus payments, so this is a revenue headwind two years out.

Guidance and outlook

From the Q3 earnings release (October 27, 2026), compared with the July guidance quoted in our Q2 report:

Nine-month adjusted EPS is already $6.45. A full-year floor of $5.20 therefore still allows an adjusted loss of up to about $1.25 per share in Q4. Some of that is seasonal: Medicare earnings fall late in the year as members use up their deductibles and copays and the plan pays more of each claim. The release does not break down the rest. The CEO said fundamentals "have powered a faster recovery to our earnings trajectory than previously anticipated."

Our read. The 2026 recovery comes from repricing Marketplace plans and growing the drug-plan business. The 2027 question is about what Centene loses:

• the California immigration-status members (about 175,000);
• the Hawaii and Florida Children's Medical Services contracts;
• possibly Georgia and Texas, where Centene is protesting the procurement results;
• Health Net's commercial group business, which is being discontinued;
• Medicaid members affected by the One Big Beautiful Bill Act's work requirements and more frequent eligibility checks, which start largely in 2027.

Against these, Centene was re-awarded the Illinois Medicaid contract from 2027. Watch the Medicaid HBR. If it stays at around 93.5% while membership keeps shrinking, the cost-cutting program has to make up the difference, and Q4 will show how much more severance it takes.